001     126257
005     20240228140818.0
024 7 _ |a 10.1016/j.stemcr.2015.03.005
|2 doi
024 7 _ |a pmid:25921812
|2 pmid
024 7 _ |a pmc:PMC4437464
|2 pmc
024 7 _ |a altmetric:3973369
|2 altmetric
037 _ _ |a DKFZ-2017-02372
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Cheng, Peng
|b 0
245 _ _ |a Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells.
260 _ _ |a Maryland Heights, MO
|c 2015
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1508404286_7026
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Glioblastoma is a highly lethal cancer for which novel therapeutics are urgently needed. Two distinct subtypes of glioblastoma stem-like cells (GSCs) were recently identified: mesenchymal (MES) and proneural (PN). To identify mechanisms to target the more aggressive MES GSCs, we combined transcriptomic expression analysis and kinome-wide short hairpin RNA screening of MES and PN GSCs. In comparison to PN GSCs, we found significant upregulation and phosphorylation of the receptor tyrosine kinase AXL in MES GSCs. Knockdown of AXL significantly decreased MES GSC self-renewal capacity in vitro and inhibited the growth of glioblastoma patient-derived xenografts. Moreover, inhibition of AXL with shRNA or pharmacologic inhibitors also increased cell death significantly more in MES GSCs. Clinically, AXL expression was elevated in the MES GBM subtype and significantly correlated with poor prognosis in multiple cancers. In conclusion, we identified AXL as a potential molecular target for novel approaches to treat glioblastoma and other solid cancers.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antigens, CD44
|2 NLM Chemicals
650 _ 7 |a Proto-Oncogene Proteins
|2 NLM Chemicals
650 _ 7 |a RNA, Small Interfering
|2 NLM Chemicals
650 _ 7 |a Receptor Protein-Tyrosine Kinases
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a axl receptor tyrosine kinase
|0 EC 2.7.10.1
|2 NLM Chemicals
700 1 _ |a Phillips, Emma
|0 P:(DE-He78)830be4979a39935ac6272eaebad5982a
|b 1
|u dkfz
700 1 _ |a Kim, Sung-Hak
|b 2
700 1 _ |a Taylor, David
|b 3
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 4
|u dkfz
700 1 _ |a Puccio, Laura
|0 P:(DE-He78)39a8becd6fa9602e4871d18f3f6f8e09
|b 5
|u dkfz
700 1 _ |a Hjelmeland, Anita B
|b 6
700 1 _ |a Lichter, Peter
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 7
|u dkfz
700 1 _ |a Nakano, Ichiro
|b 8
700 1 _ |a Goidts, Violaine
|0 P:(DE-HGF)0
|b 9
|e Last author
773 _ _ |a 10.1016/j.stemcr.2015.03.005
|g Vol. 4, no. 5, p. 899 - 913
|0 PERI:(DE-600)2720528-9
|n 5
|p 899 - 913
|t Stem cell reports
|v 4
|y 2015
|x 2213-6711
909 C O |o oai:inrepo02.dkfz.de:126257
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)830be4979a39935ac6272eaebad5982a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)39a8becd6fa9602e4871d18f3f6f8e09
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b STEM CELL REP : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version)
|0 LIC:(DE-HGF)CCBYNCNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b STEM CELL REP : 2015
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l Molekulare Genetik
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
920 1 _ |0 I:(DE-He78)B067-20160331
|k B067
|l Translationale Zielmoleküle für Hirntumoren
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)B067-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21